Unknown

Dataset Information

0

Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men.


ABSTRACT: Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive pulmonary disease. The excretion balance and pharmacokinetics of batefenterol using [14 C]-radiolabeled drug administered orally and as intravenous (IV) infusion were assessed. In this 2-period, open-label study, 6 healthy male subjects received a single IV microtracer 1-hour infusion of 4 μg [14 C]-batefenterol concomitant with inhaled nonradiolabeled batefenterol (1200 μg) followed by oral [14 C]-batefenterol (200 μg) in period 2 after a 14-day washout. The primary end points included: the area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC0-t ); maximum observed concentration (Cmax ); and time of occurrence of maximum observed concentration. Following IV administration, the geometric mean AUC0-t of [14 C]-batefenterol was 121.9 pgEq • h/mL; maximum observed concentration and time of occurrence of maximum observed concentration were 92.7 pgEq/mL and 0.8 hours, respectively; absolute oral bioavailability was 0.012%. The mean AUC0-t ratio indicated that [14 C]-batefenterol accounted for 85% of total circulating radioactivity in the plasma initially and declined rapidly following IV administration, but only ∼0.2% of total circulating radioactivity following oral administration. Cumulative mean recovery of total radioactive [14 C]-batefenterol in urine and feces was 6.31% and 77.6%, respectively. Overall, batefenterol exhibited low systemic bioavailability after inhaled and oral administration, and high fecal excretion and low urinary excretion following IV and oral administration.

SUBMITTER: Ambery C 

PROVIDER: S-EPMC6282586 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics, Excretion, and Mass Balance of [<sup>14</sup> C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men.

Ambery Claire C   Young Graeme G   Fuller Teresa T   Lazaar Aili L AL   Pereira Adrian A   Hughes Adam A   Ramsay David D   van den Berg Frans F   Daley-Yates Peter P  

Clinical pharmacology in drug development 20180919 8


Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive pulmonary disease. The excretion balance and pharmacokinetics of batefenterol using [<sup>14</sup> C]-radiolabeled drug administered orally and as intravenous (IV) infusion were assessed. In this 2-period, open-label study, 6 healthy male subjects received a single IV microtracer 1-hour infusion of 4 μg [<sup>14</sup> C]-batefenterol concomitant with inhaled nonradiolabeled batefenterol (120  ...[more]

Similar Datasets

| S-EPMC5247555 | biostudies-literature
| S-EPMC8901509 | biostudies-literature
| S-EPMC8765310 | biostudies-literature
| S-EPMC9322294 | biostudies-literature
| S-EPMC5344956 | biostudies-literature
| S-EPMC5754411 | biostudies-literature
| S-EPMC7689753 | biostudies-literature
| S-EPMC7878185 | biostudies-literature
| S-EPMC7960626 | biostudies-literature
| S-EPMC8184462 | biostudies-literature